Form 4: AnaptysBio Director Dennis M. Fenton Acquires Stock Options and Restricted Stock Units

Director Dennis M. Fenton acquired stock options and restricted stock units in AnaptysBio, Inc. on January 7, 2025.

Summary

• On January 7, 2025, Dennis M. Fenton, a director of AnaptysBio, Inc., acquired 16,510 stock options with an exercise price of $14.83 and 6,030 restricted stock units (RSUs).
• The stock options vest monthly, starting February 7, 2025, over a 12-month period, contingent upon continued service to the company.
• The RSUs vest 100% on the date of the Issuer's 2026 annual meeting of shareholders, also subject to continued service.
• Following these transactions, Fenton directly owns 16,510 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock options and RSU grants. It indicates alignment of interests but doesn't necessarily imply a strong positive or negative outlook.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedules tied to continued service align the director's interests with those of the shareholders.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest a continued commitment from the director to the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the insider activity positively, as it aligns the director's interests with the company's performance.
• Employees may see this as a positive sign of management's commitment.

Key Dates